Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABP-6118
- Development stage
- Preclinical
- Lead developer
- Atom Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABP-6118 is a small molecule chemical drug under preclinical development as an inhibitor of xanthine oxidase (XO), also known as xanthine dehydrogenase. Its primary mechanism of action is the inhibition of XO, which plays a key role in purine metabolism by catalyzing the oxidation of hypoxanthine to xanthine and then to uric acid. By inhibiting XO, ABP-6118 aims to reduce uric acid production and is being developed for the treatment of gout—a metabolic disease characterized by elevated levels of uric acid leading to joint inflammation. The drug is being developed by Hangzhou Atom Therapeutics Co., Ltd., with its main indication currently listed as gout[1][3][4].
02
Targets
XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on ABP-6118.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABP-6118.